Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Dec;88(6):611-4.
doi: 10.1136/heart.88.6.611.

Beta blockers in older persons with heart failure: tolerability and impact on quality of life

A J Baxter  1 , A Spensley, A Hildreth, G Karimova, J E O'Connell, C S Gray
Affiliations

Beta blockers in older persons with heart failure: tolerability and impact on quality of life

A J Baxter et al. Heart. 2002 Dec.

Abstract

Objective: To determine tolerability and symptom changes associated with the introduction of bisoprolol treatment in older patients with heart failure.

Design: Prospective observational cohort study.

Setting: Geriatric medicine outpatient department of a university hospital.

Patients: 51 patients (mean age 78 years, range 70-89 years) with stable symptomatic heart failure caused by left ventricular systolic dysfunction.

Interventions: Bisoprolol tablets, 1.25-10.0 mg.

Main outcome measures: Tolerability; changes in symptoms and exercise tolerance.

Results: 69% of patients tolerated bisoprolol. Mean tolerated dose was 7.6 mg. There was no change in symptoms or exercise capacity in those who tolerated bisoprolol. Perceived health status and symptoms of anxiety and depression improved during the titration period.

Conclusions: The rate of withdrawal from bisoprolol treatment in older patients with congestive heart failure was twice that previously reported in younger patients. The mean tolerated dose was similar to that found in trials reporting clinical efficacy. There was no evidence of a negative impact on symptoms or exercise capacity in patients who tolerated bisoprolol.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in mean systolic and diastolic blood pressure during the test dose observation period.
See this image and copyright information in PMC

References

    1. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. - PubMed
    1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–7. - PubMed
    1. Sharpe N. Benefit of β-blockers for heart failure: proven in 1999. Lancet 1999;353:2000. - PubMed
    1. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure: a population based study. Eur Heart J 1999;6:421–8. - PubMed
    1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–25. - PubMed

Publication types

MeSH terms